Dr. Daniel Teper of Immune Pharmaceuticals reports

IMMUNE PHARMACEUTICALS TO EXPAND BULLOUS PEMPHIGOID CLINICAL DEVELOPMENT PLAN FOR BERTILIMUMAB

iCo Therapeutics Inc. licensee Immune Pharmaceuticals Inc. intends to expand its planned bullous pemphigoid (BP) clinical development for bertilimumab, a fully human monoclonal antibody targeting eotaxin-1. Bullous pemphigoid is an orphan auto-immune blistering disease of the skin affecting approximately 60,000 patients in the United States and Europe.

As previously announced, Immune expects to start enrolling patients in a phase II clinical trial in Israel to be treated during the second quarter of 2015. Additionally, following an international medical advisory board meeting held in San Francisco immediately prior to the American Academy of Dermatology annual meeting, Immune has decided to expand its clinical program to include U.S. centres in the phase II BP development program. The company also intends to initiate studies to further investigate the relationship between eotaxin-1 levels and the bullous pemphigoid disease area activity index (BPDAI), and to assess the burden of illness from a medical and economic standpoint. Immune has formed an international medical advisory board for the development of bertilimumab in BP, with key opinion leaders including Prof. Neil Korman (Case Western, Cleveland, U.S.), Prof. Russell Hall (Duke University, U.S.), Prof. Pascal Joly (Rouen, France) and Prof. Dedee Murrell (Sydney, Australia).

"Immune Pharmaceuticals is committed to better understanding this orphan disease and improving clinical outcomes and quality of life for patients with bullous pemphigoid and other auto-immune diseases," said Dr. Daniel Teper, chief executive officer of Immune Pharmaceuticals.

About Immune Pharmaceuticals Inc.

Immune Pharmaceuticals Inc. applies a personalized approach to treatment, developing novel, highly targeted antibody therapeutics to improve the lives of patients with inflammatory diseases and cancer. The company's lead product candidate, bertilimumab, is in clinical development for moderate to severe ulcerative colitis and Crohn's disease as well as bullous pemphigoid, an orphan auto-immune dermatological condition. Immune licensed worldwide rights for systemic indications of bertilimumab from iCo Therapeutics Inc. in June, 2011, while iCo retained rights to all ophthalmic indications. iCo originally licensed the exclusive worldwide rights to bertilimumab in 2006 from MedImmune, the global research and development arm of AstraZeneca. Immune's pipeline also includes NanomAbs, antibody nanoparticle conjugates, for the targeted delivery of chemotherapeutics, and AmiKet, a neuropathic pain drug candidate ready for phase III. AmiKet has received orphan drug designation for postherpetic neuralgia.

We seek Safe Harbor.